little oversight over doses of radiation administered. In 1986, however, the institution created new consent forms for oblating patients. Dr. Podoloff explains that this instituted a new process that eventually “humanized” radiology research by building in a view of the patient receiving experimental treatment. As part of this discussion, Dr. Podoloff talks about the ethical complexities in Dr. Emil J Freireich’s work [Oral History Interview] and work in Developmental Therapeutics, where researchers often gave extremely high doses of drugs. Dr. Podoloff says he faces a current dilemma in his own research, and he is considering whether questions about dosages of IPQA will prevent him moving forward with clinical trials. Dr. Podoloff next o...
In this chapter, Dr. Alexanian talks about the difficulty in defining cure when discussing cancer,...
Dr. Cox describes the research he undertook when left the position of Vice President for Patient Car...
Dr. Alexanian offers his views on the regulatory climate at MD Anderson, another source of difficu...
little oversight over doses of radiation administered. In 1986, however, the institution created ne...
In this chapter, Dr. Gehan talks about Dr. Jan VanEys’ work in pediatrics and as an ethicist at MD A...
Dr. Podoloff speaks broadly of advances in radiology research. He first states that conservatism in ...
Dr. Buzdar begins this chapter by describing the overall culture of medical conservatism he and othe...
In this chapter, Dr. Benjamin talks about his work with anthracyclines and daunorubicin at the Balti...
In this segment, Dr. Podoloff explains the major technological breakthroughs that transformed the pr...
In this section, Dr. Alexanian comments on the uneven focus on innovative research among the faculty...
Whereas scientific evidence is the basis for recommendations and guidance on radiological protection...
Dr. Podoloff lists some of the immediate issues that have to be addressed in developing the Center f...
Dr. Freireich begins this chapter by sketching the educational opportunities that MD Anderson offers...
Breast and prostate cancer survivors and advocates partici-pated as panelists with scientists in an ...
Dr. Podoloff talks about the need for growth at MD Anderson and sketches expansion has had an impact...
In this chapter, Dr. Alexanian talks about the difficulty in defining cure when discussing cancer,...
Dr. Cox describes the research he undertook when left the position of Vice President for Patient Car...
Dr. Alexanian offers his views on the regulatory climate at MD Anderson, another source of difficu...
little oversight over doses of radiation administered. In 1986, however, the institution created ne...
In this chapter, Dr. Gehan talks about Dr. Jan VanEys’ work in pediatrics and as an ethicist at MD A...
Dr. Podoloff speaks broadly of advances in radiology research. He first states that conservatism in ...
Dr. Buzdar begins this chapter by describing the overall culture of medical conservatism he and othe...
In this chapter, Dr. Benjamin talks about his work with anthracyclines and daunorubicin at the Balti...
In this segment, Dr. Podoloff explains the major technological breakthroughs that transformed the pr...
In this section, Dr. Alexanian comments on the uneven focus on innovative research among the faculty...
Whereas scientific evidence is the basis for recommendations and guidance on radiological protection...
Dr. Podoloff lists some of the immediate issues that have to be addressed in developing the Center f...
Dr. Freireich begins this chapter by sketching the educational opportunities that MD Anderson offers...
Breast and prostate cancer survivors and advocates partici-pated as panelists with scientists in an ...
Dr. Podoloff talks about the need for growth at MD Anderson and sketches expansion has had an impact...
In this chapter, Dr. Alexanian talks about the difficulty in defining cure when discussing cancer,...
Dr. Cox describes the research he undertook when left the position of Vice President for Patient Car...
Dr. Alexanian offers his views on the regulatory climate at MD Anderson, another source of difficu...